Skip to content
Peptide research

Dulaglutide

Also known as Trulicity
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

An injectable GLP-1 receptor agonist for type 2 diabetes, also used off-label for weight loss. Unlike many peptides here, the case rests on large human trials, not animal or mechanism data: solid evidence for HbA1c reduction, weight loss, and cardiovascular risk reduction, with low hypoglycemia risk. Main concerns are common GI side effects and a theoretical, boxed-warning risk of thyroid tumors in rodents. FDA-approved (Trulicity), prescription-only.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Glycemic control (HbA1c reduction)

    High

    Large randomized trials show dose-dependent HbA1c reductions of about 1.5 to 1.9 percent.

  • Cardiovascular risk reduction

    High

    Dedicated cardiovascular trial showed modest risk reduction, driven mainly by fewer strokes.

  • Weight loss

    High

    Human trials show modest weight loss, about 3 to 5 kg, not FDA-approved for weight management.

Evidence limits

Evidence Level
Level 1 — Strong

Dulaglutide has strong cardiovascular outcomes evidence from REWIND (N=9,901; median follow-up 5.4 years), a large GLP-1 receptor agonist cardiovascular outcomes trial with long follow-up. The AWARD program includes 11+ phase III RCTs demonstrating consistent glycemic efficacy across monotherapy and combination therapy settings. Head-to-head trials have shown superiority over metformin, sitagliptin, and exenatide, and non-inferiority to liraglutide and insulin glargine.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of MTC

    Absolute

    FDA boxed warning for thyroid C-cell tumor risk. Contraindicated in MTC/MEN2.

  • History of pancreatitis

    High

    Monitor for and discontinue if pancreatitis occurs. Acute pancreatitis reported in trials.

  • Severe gastroparesis

    High

    GLP-1 agonist slows gastric emptying. Avoid with severe gastroparesis.

  • Severe renal impairment

    Moderate

    GI-related dehydration may worsen renal function. Monitor closely.

General cautions

  • Pregnancy

    Absolute

    Pregnancy — precaution, not an absolute FDA contraindication. Animal studies suggest fetal risk; use during pregnancy only if the potential benefit justifies that risk.

Risk summary(8)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal adverse events

    High
  • Hypoglycemia (when combined with insulin or sulfonylureas)

    High
  • Gallbladder disease

    Moderate
  • Pancreatitis

    Low
  • Acute kidney injury

    Low
  • Serious hypersensitivity reactions

    Low
  • Cardiac conduction abnormalities

    Low
  • Thyroid C-cell tumors (boxed warning)

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.